



**(281) 719-3400**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

The information in this Current Report is being furnished pursuant to Item 7.01 of Form 8-K and, according to general instruction B.2. thereunder, the information in this Current Report shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended.

On June 4, 2012, Repros Therapeutics Inc. (the “Company”) announced that it will present an update on its Androxal® and Proellex® clinical programs at the Jefferies 2012 Global Healthcare Conference (the “Conference”) in New York, New York on Thursday, June 7, 2012, at 9:30 a.m. Eastern Standard Time. The Company is furnishing herewith as Exhibit 99.1 a copy of a slideshow presentation that it intends to present at the Conference. These slides contain statements that are “forward-looking statements” subject to the cautionary statement about forward-looking statements set forth therein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit Number	Description
----------------	-------------

99.1	Repros Therapeutics Slideshow
------	-------------------------------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 7, 2012  
Repros Therapeutics Inc.

By: /s/ Katherine A.  
Anderson  
Katherine A.  
Anderson  
Chief Financial  
Officer

**EXHIBIT INDEX**

Exhibit Number Description

99.1 Repros Therapeutics Slideshow